Use of the drugs does not lower the risk of PCa overall or of lower- or higher-risk disease.
Statin use is not associated with prostate cancer risk in men regularly screened for the malignancy, according to investigators.
Elizabeth A. Platz, ScD, MPH, of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues studied 9,457 men aged 55 years or older who were enrolled in the Prostate Cancer Prevention Trial. Over seven years of follow-up, use of a statin was not associated with PCa risk overall or the risk of lower- or higher-grade PCa, Dr. Platz’s group reported online ahead of print in The Journal of Urology.
“These prospective results do not support the hypothesis that statin drugs protect against prostate cancer in the setting of regular prostate cancer screening,” the authors concluded.
Continue Reading
Previous studies have found that men who use statins are at lower risk of aggressive PCa.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.